Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short-term Investments (2016 - 2019)

Akebia Therapeutics (AKBA) has disclosed Short-term Investments for 4 consecutive years, with $245000.0 as the latest value for Q4 2019.

  • Quarterly Short-term Investments fell 99.58% to $245000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $245000.0 through Dec 2019, down 99.58% year-over-year, with the annual reading at $245000.0 for FY2019, 99.58% down from the prior year.
  • Short-term Investments for Q4 2019 was $245000.0 at Akebia Therapeutics, down from $22.7 million in the prior quarter.
  • The five-year high for Short-term Investments was $240.1 million in Q3 2017, with the low at $245000.0 in Q4 2019.
  • Average Short-term Investments over 4 years is $130.1 million, with a median of $123.9 million recorded in 2016.
  • The sharpest move saw Short-term Investments surged 151.44% in 2017, then tumbled 99.58% in 2019.
  • Over 4 years, Short-term Investments stood at $73.0 million in 2016, then decreased by 19.58% to $58.7 million in 2017, then dropped by 0.49% to $58.4 million in 2018, then crashed by 99.58% to $245000.0 in 2019.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $245000.0, $22.7 million, and $49.6 million for Q4 2019, Q3 2019, and Q2 2019 respectively.